CURC & ARUF | Professor Tao Xu: New Perspectives on Endocrine Therapy for mHSPC — Evidence Review and Clinical Practice Centered on Enzalutamide

CURC & ARUF | Professor Tao Xu: New Perspectives on Endocrine Therapy for mHSPC — Evidence Review and Clinical Practice Centered on Enzalutamide

Prostate cancer is one of the most common malignant tumors of the male genitourinary system in China. Among these patients, metastatic hormone-sensitive prostate cancer (mHSPC) carries a particularly poor prognosis and remains a major clinical challenge. In recent years, novel hormonal therapies (NHTs), represented by enzalutamide, have continuously reshaped the treatment landscape of mHSPC. With the release of long-term follow-up data from landmark studies such as ARCHES and ENZAMET, the combination of enzalutamide plus androgen deprivation therapy (ADT) has demonstrated durable survival benefits across a broad range of subgroups, including high- and low-volume disease, synchronous and metachronous metastases, and patients treated before or after chemotherapy.
4th Clinical Research Conference on Urologic Oncology | Breaking Through the Post-PD-1 Era: Professor Xieqiao Yan Interprets the Latest Advances in Kidney Cancer Research from ASCO GU 2026

4th Clinical Research Conference on Urologic Oncology | Breaking Through the Post-PD-1 Era: Professor Xieqiao Yan Interprets the Latest Advances in Kidney Cancer Research from ASCO GU 2026

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Professor Xieqiao Yan from Peking University Cancer Hospital delivered a comprehensive presentation on the latest advances in kidney cancer therapy. His report focused on emerging clinical evidence surrounding the HIF-2α inhibitor belzutifan, particularly its evolving role in advanced clear cell renal cell carcinoma (ccRCC) after PD-1–based therapy, as well as in the postoperative adjuvant setting. The findings offer important new insights for clinical decision-making in the post-PD-1 era.
2nd Peking University Urology Academic Forum | Professor Xuesong Li: Innovation and Leadership in Integrated Management of Benign and Malignant Upper Urinary Tract Diseases

2nd Peking University Urology Academic Forum | Professor Xuesong Li: Innovation and Leadership in Integrated Management of Benign and Malignant Upper Urinary Tract Diseases

The 2nd Peking University Urology Academic Forum focused on the integrated and collaborative management of benign and malignant diseases of the upper urinary tract. As conference chair, Professor Xuesong Li from the Department of Urology at Peking University First Hospital shared his team’s long-standing experience and insights into the field’s major clinical challenges, key innovations, and future directions.
Expert Interview | Prof. Shilpa Gupta Decodes Urothelial Carcinoma In-Depth: China’s Strength, Global Collaboration and Future Breakthroughs in the ADC Era

Expert Interview | Prof. Shilpa Gupta Decodes Urothelial Carcinoma In-Depth: China’s Strength, Global Collaboration and Future Breakthroughs in the ADC Era

In recent years, the rapid advancement of antibody-drug conjugates (ADCs) has completely reshaped the treatment paradigm across the entire disease course of urothelial carcinoma. Meanwhile, Chinese investigators and domestically developed innovative agents have gained ever-increasing influence in the global oncology landscape. Recently, we had the exclusive opportunity to interview Prof. Shilpa Gupta, a world-leading expert in urothelial carcinoma, Leading Principal Investigator of multiple pivotal international multicenter clinical trials from Cleveland Clinic. We conducted an in-depth, professional exchange with Prof. Gupta on core topics including the global positioning of China's clinical research in urological oncology, optimized pathways for cross-border research collaboration, the paradigm shift in diagnosis and treatment driven by ADCs, and the future disruptive breakthrough directions in the field. The following is the edited content of this interview.
Professor Gang Zhu: Prevention and Treatment of Urologic Tumors — Early Screening Is Key, Personalized Care Enhances Patient Experience

Professor Gang Zhu: Prevention and Treatment of Urologic Tumors — Early Screening Is Key, Personalized Care Enhances Patient Experience

With the aging population and changes in lifestyle in China, the incidence of urologic cancers has been steadily increasing. Oncology Frontier – UroStream invited Professor Gang Zhu from Beijing United Family Hospital to discuss prevention strategies and personalized medical care in urologic oncology. Drawing from clinical practice, he emphasized the importance of early screening and diagnosis, as well as the unique features of international-standard medical services.
ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), one of the world’s most prestigious meetings in genitourinary oncology, multiple landmark studies were presented that are reshaping clinical practice. Among them, advances in urothelial carcinoma (UC) stood out prominently.
ASCO GU Insights | Haige Chen: Breakthroughs in Bladder Cancer and the New Era of Precision Treatment

ASCO GU Insights | Haige Chen: Breakthroughs in Bladder Cancer and the New Era of Precision Treatment

At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), held in San Francisco, leading experts from around the world gathered to present cutting-edge advances in urothelial carcinoma (UC). Key themes included antibody–drug conjugate (ADC) plus immunotherapy strategies for bladder preservation, clinical translation of liquid biopsy technologies, and deeper exploration of tumor molecular mechanisms.